Cancer Pain – Pipeline Review, H1 2020

Global Markets Direct’s, ‘Cancer Pain – Pipeline Review, H1 2020’, provides an overview of the Cancer Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cancer Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cancer Pain and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Cancer Pain

– The report reviews pipeline therapeutics for Cancer Pain by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Cancer Pain therapeutics and enlists all their major and minor projects

– The report assesses Cancer Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Cancer Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Cancer Pain

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Cancer Pain pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Alexza Pharmaceuticals Inc

AngioChem Inc

Aphios Corp

Aquilus Pharmaceuticals Inc

AstraZeneca Plc

Beckley Canopy Therapeutics Ltd

Cassava Sciences Inc

Concentric Analgesics Inc

Daewoong Pharmaceutical Co Ltd

Dompe Farmaceutici SpA

Fujimoto Pharmaceutical Corp

Hisamitsu Pharmaceutical Co Inc

Intec Pharma Ltd

IntelGenx Corp

iX Biopharma Ltd

Klaria Pharma Holding AB

Komipharm International Co Ltd

Luye Pharma Group Co Ltd

Medlab Clinical Ltd

Mundipharma International Ltd

Nanomerics Ltd

Neurocentrx Pharma Ltd

Nippon Kayaku Co Ltd

Nippon Zoki Pharmaceutical Co Ltd

Oblique Therapeutics AB

Orion Corp

Pfizer Inc

Pharmaleads SA

ProNeurogen Inc

Recordati SpA

Ribomic Inc

Sedor Pharmaceuticals LLC

Sorrento Therapeutics Inc

Tetra Bio-Pharma Inc

Virobay Inc

WEX Pharmaceuticals Inc

Winston Pharmaceuticals Inc

Yongzhan International Pharmaceutical Co Ltd

Table of Contents

Table of Contents

Introduction

Cancer Pain - Overview

Cancer Pain - Therapeutics Development

Cancer Pain - Therapeutics Assessment

Cancer Pain - Companies Involved in Therapeutics Development

Cancer Pain - Drug Profiles

Cancer Pain - Dormant Projects

Cancer Pain - Discontinued Products

Cancer Pain - Product Development Milestones

Appendix

List of Tables

List of Tables

Number of Products under Development for Cancer Pain, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Companies, H1 2020 (Contd..1), H1 2020

Products under Development by Companies, H1 2020 (Contd..2), H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Cancer Pain – Pipeline by Alexza Pharmaceuticals Inc, H1 2020

Cancer Pain – Pipeline by AngioChem Inc, H1 2020

Cancer Pain – Pipeline by Aphios Corp, H1 2020

Cancer Pain – Pipeline by Aquilus Pharmaceuticals Inc, H1 2020

Cancer Pain – Pipeline by AstraZeneca Plc, H1 2020

Cancer Pain – Pipeline by Beckley Canopy Therapeutics Ltd, H1 2020

Cancer Pain – Dormant Projects, H1 2020

Cancer Pain – Dormant Projects, H1 2020 (Contd..1), H1 2020

Cancer Pain – Dormant Projects, H1 2020 (Contd..2), H1 2020

Cancer Pain – Dormant Projects, H1 2020 (Contd..3), H1 2020

Cancer Pain – Discontinued Products, H1 2020

List of Figures

List of Figures

Number of Products under Development for Cancer Pain, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Molecule Types, H1 2020

Number of Products by Stage and Molecule Types, H1 2020

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports